Related Experiment Video
Updated: Jul 2, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Biomimetic nanotechnology for cancer immunotherapy: State of the art and future perspective
Alireza Sarkar Lotfabadi1, Banafshe Abadi2, Nima Rezaei3
1Department of Cellular and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Abstract:
Cancer continues to be a significant worldwide cause of mortality. This underscores the urgent need for novel strategies to complement and overcome the limitations of conventional therapies, such as imprecise targeting and drug resistance. Cancer Immunotherapy utilizes the body's immune system to target malignant cells, reducing harm to healthy tissue. Nevertheless, the efficacy of immunotherapy exhibits variation across individuals and has the potential to induce autoimmune responses. Biomimetic nanoparticles (bNPs) have transformative potential in cancer immunotherapy, promising improved accurate targeting, immune system activation, and resistance mechanisms, while also reducing the occurrence of systemic autoimmune side effects. This integration offers opportunities for personalized medicine and better therapeutic outcomes. Despite considerable potential, bNPs face barriers like insufficient targeting, restricted biological stability, and interactions within the tumor microenvironment. The resolution of these concerns is crucial in order to expedite the integration of bNPs from the research setting into clinical therapeutic uses. In addition, optimizing manufacturing processes and reducing bNP-related costs are essential for practical implementation. The present research introduces comprehensive classifications of bNPs as well as recent achievements in their application in cancer immunotherapies, emphasizing the need to address barriers for swift clinical integration.
Insights
Biomimetic nanoparticles (bNPs) offer improved cancer immunotherapy by enhancing targeting and reducing side effects. Addressing current limitations is key for their clinical integration and personalized cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Cancer remains a leading global cause of death, necessitating advanced therapies beyond conventional treatments.
- Current cancer immunotherapies show variable efficacy and can cause autoimmune responses.
- Biomimetic nanoparticles (bNPs) present a promising approach to enhance cancer immunotherapy.
Purpose of the Study:
- To review the classification and recent advancements of bNPs in cancer immunotherapy.
- To highlight the potential of bNPs in improving targeted delivery, immune activation, and reducing side effects.
- To identify critical barriers hindering the clinical translation of bNPs.
Main Methods:
- Comprehensive literature review on biomimetic nanoparticles for cancer immunotherapy.
- Analysis of recent research achievements and challenges in bNP applications.
- Classification of existing bNP strategies in cancer treatment.
Main Results:
- Biomimetic nanoparticles show potential for precise targeting, enhanced immune response, and minimized systemic toxicity.
- Identified challenges include insufficient targeting efficiency, limited biological stability, and tumor microenvironment interactions.
- Progress in bNP research offers opportunities for personalized medicine and improved therapeutic outcomes.
Conclusions:
- Biomimetic nanoparticles hold significant promise for revolutionizing cancer immunotherapy.
- Overcoming current limitations in targeting, stability, and manufacturing is crucial for clinical integration.
- Further research and development are needed to translate bNP potential into effective patient treatments.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...